Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone prophylaxis to reduce capsular contracture after radiotherapy in breast reconstruction
ChiCTR2600117522Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of pirfenidone in breast cancer and capsular contracture (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Incidence of Baker grade III or higher capsular contracture. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
pirfenidone
03
Conditions
breast cancercapsular contracture
Beyond the preview
Go deeper on ChiCTR2600117522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117522.